Last checked at 20 Dec 2018 07:00
20 December 2018
Proteome Sciences plc(the "Company")
Appointment of Nominated Adviser and Broker
The Board of Proteome Sciences plc is pleased to announce that Allenby Capital Limited has been appointed as the Company's new Nominated Adviser and sole Broker with immediate effect.
For further information please contact:
Proteome Sciences plc | |
Dr Jeremy Haigh, Chief Executive Officer | Tel: +44 (0)20 7043 2116 |
Dr Ian Pike, Chief Scientific Officer Richard Dennis, Chief Commercial Officer |
|
|
|
Allenby Capital Limited (Nominated Adviser & Broker) | |
John Depasquale / Jeremy Porter
| Tel: +44 (0) 20 3328 5656 |
About Proteome Sciences plc. (www.proteomics.com)
Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.
The Company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany.